CA3255143A1 - Intermediate used for fapi synthesis, preparation method therefor and application thereof - Google Patents

Intermediate used for fapi synthesis, preparation method therefor and application thereof

Info

Publication number
CA3255143A1
CA3255143A1 CA3255143A CA3255143A CA3255143A1 CA 3255143 A1 CA3255143 A1 CA 3255143A1 CA 3255143 A CA3255143 A CA 3255143A CA 3255143 A CA3255143 A CA 3255143A CA 3255143 A1 CA3255143 A1 CA 3255143A1
Authority
CA
Canada
Prior art keywords
compound
reaction
amino
formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3255143A
Other languages
English (en)
French (fr)
Inventor
Xiaoming Wu
Xiangyu WANG
Tian He
Qingbao YANG
Lin Cheng
Original Assignee
Yantai Lannacheng Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yantai Lannacheng Biotechnology Co Ltd filed Critical Yantai Lannacheng Biotechnology Co Ltd
Publication of CA3255143A1 publication Critical patent/CA3255143A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3255143A 2023-02-16 2024-02-15 Intermediate used for fapi synthesis, preparation method therefor and application thereof Pending CA3255143A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202310124318.XA CN115838393B (zh) 2023-02-16 2023-02-16 用于fapi合成的中间体及其制备方法和应用
CN202310124318.X 2023-02-16
PCT/CN2024/077215 WO2024169973A1 (zh) 2023-02-16 2024-02-15 用于fapi合成的中间体及其制备方法和应用

Publications (1)

Publication Number Publication Date
CA3255143A1 true CA3255143A1 (en) 2025-03-28

Family

ID=85579761

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3255143A Pending CA3255143A1 (en) 2023-02-16 2024-02-15 Intermediate used for fapi synthesis, preparation method therefor and application thereof

Country Status (8)

Country Link
US (1) US20250382329A1 (https=)
EP (1) EP4585607A4 (https=)
JP (1) JP7838187B2 (https=)
KR (1) KR20250022067A (https=)
CN (1) CN115838393B (https=)
CA (1) CA3255143A1 (https=)
TW (1) TWI871182B (https=)
WO (1) WO2024169973A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115838393B (zh) * 2023-02-16 2023-05-05 烟台蓝纳成生物技术有限公司 用于fapi合成的中间体及其制备方法和应用
WO2025091141A1 (zh) * 2023-10-30 2025-05-08 烟台蓝纳成生物技术有限公司 用放射性标记的截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂治疗甲状腺癌的方法
CN118754875B (zh) * 2024-09-06 2024-12-13 烟台蓝纳成生物技术有限公司 一种fapi前体化合物的制备工艺及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10696631B2 (en) * 2016-05-09 2020-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
EP3749663A1 (en) * 2018-02-06 2020-12-16 Universität Heidelberg Fap inhibitor
CN109485642A (zh) * 2018-11-21 2019-03-19 希施生物科技（上海）有限公司 一种制备伊文氏蓝衍生物的方法
EP4126053A4 (en) * 2020-03-24 2024-11-20 Trustees Of Tufts College IMAGING AGENTS AND RADIOPHARMACEUTICALS TARGETING FAP, AND USES THEREOF
CN113582975A (zh) * 2021-07-03 2021-11-02 上海蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
WO2022170732A1 (zh) * 2021-02-10 2022-08-18 上海蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
CN114369084B (zh) * 2021-02-10 2023-02-03 烟台蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
CN113004371A (zh) * 2021-03-01 2021-06-22 上海蓝纳成生物技术有限公司 一种长循环半衰期的前列腺特异性膜抗原靶向化合物及其制备方法和应用
CN113603678A (zh) * 2021-08-10 2021-11-05 上海蓝纳成生物技术有限公司 一种靶向成纤维细胞活化蛋白的诊断药物及其制备方法
CN113621021A (zh) * 2021-08-10 2021-11-09 上海蓝纳成生物技术有限公司 一种靶向成纤维细胞活化蛋白的治疗药物及其制备方法
CN115677829A (zh) * 2022-10-19 2023-02-03 广州华复生物科技有限公司 一种糖基化靶向fap化合物、靶向fap标记配合物及其制备方法与应用
CN115838393B (zh) * 2023-02-16 2023-05-05 烟台蓝纳成生物技术有限公司 用于fapi合成的中间体及其制备方法和应用

Also Published As

Publication number Publication date
WO2024169973A1 (zh) 2024-08-22
TW202434565A (zh) 2024-09-01
EP4585607A4 (en) 2026-03-25
US20250382329A1 (en) 2025-12-18
JP7838187B2 (ja) 2026-03-31
EP4585607A1 (en) 2025-07-16
CN115838393B (zh) 2023-05-05
JP2025534068A (ja) 2025-10-09
TWI871182B (zh) 2025-01-21
CN115838393A (zh) 2023-03-24
KR20250022067A (ko) 2025-02-14

Similar Documents

Publication Publication Date Title
EP4585607A1 (en) Intermediate used for fapi synthesis, preparation method therefor, and application thereof
CN115286697A (zh) 一种双重靶向化合物及其制备方法和应用
CN115505032B (zh) 一种成纤维细胞活化蛋白FAP和整合素αvβ3双重靶向化合物及其制备方法和应用
JP2026501617A (ja) Ｎ－ハロアルキル置換カンプトテシン誘導体の抗体複合薬物
JP7837971B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）リガンドの合成
JP2021518847A (ja) アマニチン類抗体複合物
WO2026016269A1 (zh) 一种用于主动靶向表皮生长因子受体检测的近红外荧光探针及其制备方法与应用
CN118978511A (zh) 一种靶向fap化合物及其制备方法
CN117343125B (zh) 一种抗体偶联药物连接子的合成方法
RU2846888C2 (ru) Промежуточное соединение для синтеза fapi, способ его получения и применение
KR20260025869A (ko) Fap 표적화 화합물, 이에 기반한 방사성 핵종 표지 착물 및 그 제조 방법과 응용
CN113149966A (zh) Nir/pet双模态造影剂及其制备方法与应用
WO2023033017A1 (ja) ガニレリクス又はその塩の製造法
CN115572320A (zh) 一种前列腺癌分子探针及其制备方法与应用
CN107365352A (zh) 一种新型含9‑腺嘌呤丙氨酸的三肽化合物及其制备方法和应用
WO2008075966A9 (en) Synthesis of a radiofluorinated peptide using photolabile protecting groups
CN106083737A (zh) 一种可用于肿瘤治疗的嘧啶类丙氨酸衍生物及其制备方法和应用
JP2002539132A (ja) ２０（ｓ）−カンプトテシンの糖−共役体の製造法
CN116284255B (zh) 一种用于早期结直肠肿瘤的靶向多肽化合物与应用
CN106083856A (zh) 一种可用于肿瘤治疗的嘌呤类丙氨酸衍生物及其制备方法和应用
RU2838403C1 (ru) СОЕДИНЕНИЕ ДВОЙНОГО НАЦЕЛИВАНИЯ ДЛЯ БЕЛКА АКТИВАЦИИ ФИБРОБЛАСТОВ (FAP) И ИНТЕГРИНА αvβ3, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ
TWI910785B (zh) 一種連接子-藥物的製備方法
CN114288426B (zh) 艾替班特及其衍生物在制备肿瘤诊断和/或治疗试剂中的应用
WO2024260421A1 (zh) 一种类肽化合物及其配合物、药物组合物和应用
CN119954773A (zh) Psma化合物、包含其的药物组合物及其用途

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241119

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241119

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241128

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20241128

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250218

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250218

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250221

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250321

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250321

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250321

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250324

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250324

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250324

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-2-2-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20250328

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251029

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251029

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251208

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260123

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260126

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260126